BIOCYTOGEN-B (02315) rose nearly 13% following its positive profit alert. As of writing, the stock was up 8.82%, trading at HK$47.88 with a turnover of HK$27.715 million. The company released its 2025 annual performance forecast, anticipating total revenue to reach approximately RMB 1.369 billion to RMB 1.389 billion. This represents an increase of RMB 389 million to RMB 408 million compared to the previous year, a year-on-year growth of 39.61% to 41.65%. Attributable net profit is expected to be around RMB 162 million to RMB 182 million, marking an increase of RMB 129 million to RMB 149 million from the prior year. This signifies a substantial year-on-year surge of 384.26% to 443.88%. The announcement stated that the company's rapid revenue growth is driven by continued expansion in overseas markets, coupled with a recovery in the domestic biopharmaceutical industry. High-barrier technological advantages ensure gross margins remain elevated, while lean management initiatives further enhance operational efficiency, leading to a rapid improvement in profitability.